All In Biotech

Drug Trial Radar · NCT04229004

A Multi-center Trial to Evaluate Multiple Regimens in Metastatic Pancreatic Cancer

Precision Promise Platform Trial for Metastatic Pancreatic Cancer

Last checked: Nov 19, 2026Latest source record: Apr 6, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 502 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

502

Actual

Start

Jan 31, 2020

Primary completion

Feb 5, 2025

Study completion Feb 5, 2025

Sponsor

Lead sponsor
Pancreatic Cancer Action NetworkAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jan 14, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Precision Promise is a multi-center, seamless Phase 2/3 platform trial designed to evaluate multiple regimens in metastatic pancreatic cancer. Primary Objectives * To compare each investigational arm versus standard of care (SOC) for superiority in overall survival in first and/or second line metastatic ductal adenocarcinoma (metastatic pancreatic cancer) participants and determine which, if any, participants benefit from each investigational arm. Secondary Objectives * To determine short and long-term safety signals of each investigational arm in metastatic pancreatic cancer participants vs. SOC. * To determine progression-free survival (PFS) for each investigational arm vs. SOC. * To determine rates of overall response, CR, and PR; duration of overall response, CR or PR (whichever occurs first). * To determine rates of clinical benefit; duration of clinical benefit.

Conditions

  • Metastatic Pancreatic Cancer
  • Metastatic Pancreatic Adenocarcinoma

Interventions

  • Gemcitabine combined with nab-paclitaxelDrug

    Arm is closed to recruitment. Nab-paclitaxel is infused over 30-40 min on days 1, 8, 15 of each 28-day cycle. Gemcitabine is infused over 30 min, immediately after completion of nab-paclitaxel infusion, on days 1, 8, 15 of each 28-day cycle. If one of the chemotherapy medications is held, the other study medications may be given. Doses should be re-adjusted if the participant's weight changes by +/- \>10%. If the participant's weight changes by \<10%, no adjustment is necessary unless the site has a standard procedure to adjust doses based upon current weight according to institutional guidelines.

  • Dose -mFOLFIRINOXDrug

    Arm is closed to recruitment. The following are recommended parameters for infusion timing and sequence, although institutional variation in the administration of the regimen are permitted, as long as drug dosing and modification guidelines are followed. Oxaliplatin and leucovorin are administered concurrently over 30-120 minutes, followed by irinotecan over 30-90 minutes, followed by the infusion of 5-flurouracil. If one of the chemotherapy medications is held, the other study medications may be given. Doses should be re-adjusted if the participant's weight changes by +/- \>10%. If the participant's weight changes by \<10%, no adjustment is necessary unless the site has a standard procedure to adjust doses based upon current weight according to institutional guidelines.

  • Dose - Pamrevlumab combined with gemcitabine and nab-paclitaxelDrug

    Arm is closed to recruitment. Pamrevlumab 35mg/kg IV - Cycle 1 (Day 1, 8, 15 of the 28 day cycle) and Cycle 2 and Onward (Day 1 and 15) Nab-paclitaxel 125mg/m2 IV - Day 1, 8, 15 for every 28 day cycle Gemcitabine 1000mg/m2 IV - Day 1, 8, 15 for every 28 day cycle

  • Dose- Canakinumab and Spartalizumab combined with nab-paclitaxel and gemcitabineDrug

    Arm is closed to recruitment. Canakinumab 250mg SC- Day 1 of every 28 day cycle Spartalizumab 400 mg IV - Day 1 of every 28 day cycle Nab-paclitaxel 125mg/m2 IV - Day 1, 8, 15 of every 28 day cycle Gemcitabine 1000mg/m2 IV - Day 1, 8, 15 of every 28 day cycle

  • Drug: Dose -SM-88Drug

    Arm is closed to recruitment. 460 mg (2 capsules) twice daily of a 28-day cycle along with the administration of methoxsalen, phenytoin and sirolimus.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall SurvivalTime frame: 0 weeks

Locations

25 sites in 1 country. Site status is shown where the registry gives one.

  • University of California, San Diego (UCSD) - Moores Cancer Center

    La Jolla, California

  • Cedars-Sinai Medical Center

    Los Angeles, California

  • University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center

    San Francisco, California

  • University of Florida College of Medicine

    Gainesville, Florida

  • Sylvester Comprehensive Cancer Center

    Miami, Florida

  • The University of Chicago Medical Center

    Chicago, Illinois

  • Johns Hopkins Medicine - The Sidney Kimmel Comprehensive Cancer Center

    Baltimore, Maryland

  • Dana-Farber Cancer Institute

    Boston, Massachusetts

  • University of Michigan - Rogel Cancer Center

    Ann Arbor, Michigan

  • Mayo Clinic Cancer Center (MCCC)

    Rochester, Minnesota

  • Siteman Cancer Center - Washington University Medical Campus

    St Louis, Missouri

  • University of New Mexico Comprehensive Cancer Center

    Albuquerque, New Mexico

  • New York University Langone Medical Center - Perlmutter Cancer Center

    New York, New York

  • Evelyn H. Lauder Breast Center - Memorial Sloan Kettering Cancer Center

    New York, New York

  • Weill Cornell Physicians - Solid Tumor/Gastrointestinal Oncology

    New York, New York

  • University of Cincinnati Cancer Institute

    Cincinnati, Ohio

  • University of Pennsylvania - Abramson Cancer Center

    Philadelphia, Pennsylvania

  • The University of Texas Southwestern Medical Center

    Dallas, Texas

  • Baylor College of Medicine

    Houston, Texas

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas

  • Huntsman Cancer Institute

    Salt Lake City, Utah

  • Virginia Commonwealth University School of Medicine

    Richmond, Virginia

  • Virginia Mason Hospital & Seattle Medical Center

    Seattle, Washington

  • Fred Hutchinson Cancer Research Center

    Seattle, Washington

  • Medical College of Wisconsin

    Milwaukee, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.